Cell Therapy Bioreactors Market Report 2026

The cell therapy bioreactors market size has grown rapidly in recent years. It will grow from $1.24 billion in 2025 to $1.44 billion in 2026 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to increasing demand for cell-based therapies, growing investment in regenerative medicine, rising adoption of automated cell culture systems, expansion of stem cell research, and increasing need for scalable cell production.

The cell therapy bioreactors market size is expected to see rapid growth in the next few years. It will grow to $2.61 billion in 2030 at a compound annual growth rate (CAGR) of 16%. The growth in the forecast period can be attributed to growing adoption of cell therapy bioreactors in manufacturing, rising investment in advanced bioprocessing technologies, increasing focus on process optimization and quality control, expansion of clinical trials involving cell therapies, and growing demand for personalized medicine applications. Major trends in the forecast period include advancements in automated cell culture technologies, innovations in bioreactor design for enhanced scalability, developments in stem cell expansion platforms, research and development in process monitoring and control systems, and emerging upgrades in integrated cell therapy manufacturing solutions.

The growing demand for gene therapies is expected to propel the growth of the cell therapy bioreactors market going forward. Gene therapy refers to a medical technique that involves modifying or replacing defective genes to treat or prevent diseases. The increasing demand for gene therapy is due to advancements in genetic sequencing and diagnostics, which enable precise identification of disease-causing genes for targeted treatment. Cell therapy bioreactors accelerate gene therapies by providing optimized environments for the growth, modification, and expansion of therapeutic cells. They enhance treatment development and scalability by ensuring consistent cell quality, improving efficiency, and supporting faster production of personalized gene-based therapies. For instance, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved 6 gene therapy products in 2023, up from 5 approvals in 2022. Therefore, the growing demand for gene therapies is driving the growth of the cell therapy bioreactors market.

The rising prevalence of chronic diseases is anticipated to drive the growth of the cell therapy bioreactors sector in the coming years. Chronic and rare diseases encompass long-term health conditions and uncommon disorders that often necessitate specialized treatment strategies, including personalized and regenerative therapies. The increase in chronic diseases is largely attributed to unhealthy lifestyles, such as poor diet, physical inactivity, and smoking, which elevate the risk of ailments like diabetes, heart disease, and obesity. Cell therapy bioreactors aid in managing chronic diseases by providing controlled environments for the cultivation and expansion of therapeutic cells. They improve treatment efficacy and scalability by maintaining consistent cell quality, facilitating personalized therapies, and supporting long-term patient care. For example, in 2025, the International Diabetes Federation, a Belgium-based health organization, reported that approximately 589 million adults aged 20-79 were living with diabetes in 2024, with the total expected to rise to 853 million by 2050. Consequently, the growing prevalence of chronic and rare diseases is fueling the expansion of the cell therapy bioreactors sector.

Major companies operating in the cell therapy bioreactors sector are concentrating on developing advanced platforms, such as modular, multi-scale bioreactor systems, to enhance process scalability, cell expansion efficiency, and consistency from early research to commercial production. A modular multi-scale bioreactor system is a versatile setup that allows researchers to perform parallel small-scale experiments, optimize conditions, and seamlessly scale up to mid- or large-scale production while maintaining uniform culture conditions and high yields. For example, in July 2024, EXO-Harvest, a Belgium-based biomanufacturing technology firm, introduced its state-of-the-art multi-scale bioreactor platform for efficient production of mesenchymal stem cells and extracellular vesicles, supporting scalable adherent cell culture from discovery to industrial manufacturing. The platform comprises small-scale multi-bioreactor screening and mid/large-scale systems designed to accelerate development, reduce costs, and deliver high-quality cultures with precise environmental control.

Major companies operating in the cell therapy bioreactors market are Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Danaher Corporation, Corning Incorporated, Lonza Group, Terumo Corporation, Sartorius AG, Eppendorf AG, Miltenyi Biotec B.V. & Co. KG, PBS Biotech Inc., Meissner Filtration Products Inc., Infors AG, Bionet Engineering & Technologies Pvt. Ltd., Wilson Wolf Manufacturing Corporation, Synthecon Incorporated, Cellexus Limited, Celartia Inc., Able Biott Inc., CelVivo ApS.

North America was the largest region in the cell therapy bioreactors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy bioreactors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell therapy bioreactors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have influenced the cell therapy bioreactor market by increasing the cost of imported bioreactor components and culture media, impacting production timelines and supply chain efficiency. high tariffs particularly affect single-use and advanced automated systems imported into regions such as north america and europe. stem cell and immune cell production segments face significant cost pressures, while local manufacturing initiatives may benefit from increased domestic demand. overall, tariffs encourage innovation in cost-effective manufacturing solutions while presenting challenges for global suppliers.

Cell therapy bioreactors are advanced systems engineered to support the controlled growth, expansion, and differentiation of cells for therapeutic purposes. They offer a regulated environment with precise control over parameters such as temperature, pH, oxygen, and nutrient supply to ensure cell viability and functionality. By allowing scalable and reproducible cell production, these bioreactors support the development and manufacturing of sophisticated cell-based therapies.

The main products in cell-therapy bioreactors include stirred-tank bioreactors, wave-induced bioreactors, fixed-bed bioreactors, and others. Stirred-tank systems agitate cultures for uniform growth, while wave-induced systems mix gently using rocking motion. Cell types include stem cells, immune cells, differentiated cells, and others. Systems may be single-use or reusable. Applications span research, clinical studies, and commercial manufacturing, serving pharmaceutical companies, research institutes, CMOs, and others.

The cell therapy bioreactors market consists of sales of bioreactor vessels, control systems, single-use bioreactor units, perfusion bioreactors, and monitoring and automation equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.